Anti-TCR [BMA031]

Absolute Antibody

Anti-TCR [BMA031]

9

This antibody reacts with surface receptors on all alpha-beta TCR bearing cells, but does not react with receptors on gamma-delta T cells. TCR-alphabeta is expressed by the majority of mature CD3+ T cells.

This antibody is recomended for detection of viable human alphabeta+ TCR lymphocyte. It is highly effective in modulating immune reactions and is capable of activating human T lymphocytes in vito (PMID: 3092794). Double immunofluorescence staining was used to ascertain that this antibody does not cross react with gammadelta+ TCR cells. FACS analysis confirmed that BMA031 did not react with gammadelta+ TCR cells. BMA031 successfully precipitates TCR alphabeta/CDR complex (PMID: 1704361). BMA031 in conjugation with triple drug induction treatment in kidney-transplanted patients showed no side effects and reduction in graft rejections (PMID: 2978369). A clinical phase II trial administered 50 mg of murine anti-human alpha/beta-TCR mAb (BMA 031) intravenously on the day of, as well as 2 and 4 days after, cadaveric donor renal transplantation in combination with a CsA/prednisone regimen. After a minimum of 30 months follow-up, the actual allograft survival rate was 87% in the BMA-treated group compared with 68% in the control cohort (PMID: 8009591).Humanized version of this antibody BMA 031-EUCIV3 is found to have 2.5 times less affinity than its murine parent, however the ability to cause antibody dependent cell-mediated cytolysis was significantly enhanced (PMID: 1836485).

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Neutralisation/Blocking

Research Use Only

Monoclonal

BMA031

Human

IgG1

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203